BACKGROUND AND PURPOSE: One important syndrome of psychiatric disorders in humans is catalepsy. Here, we created mice with different predispositions to catalepsy and analysed their pharmacological and behavioural properties. EXPERIMENTAL APPROACH: Two mouse lines, B6-M76C and B6-M76B, were created by transfer of the main locus of catalepsy containing the 5-HT1A receptor gene to the C57BL/6 genetic background. Behaviour, brain morphology, expression of key components of the serotoninergic system, and pharmacological responses to acute and chronic stimulation of the 5-HT1A receptor were compared. KEY RESULTS: B6-M76B mice were not cataleptic, whereas 14% of B6-M76C mice demonstrated catalepsy and decreased depressive-like behaviour. Acute administration of the 5-HT1A receptor agonist 8-OH-DPAT resulted in dose-dependent hypothermia and in decreased locomotion in both lines. Chronic 8-OH-DPAT administration abolished the 5-HT1A receptor-mediated hypothermic response in B6-M76C mice and increased locomotor activity in B6-M76B mice. In addition, 5-HT metabolism was significantly reduced in the hippocampus of B6-M76C mice, and this effect was accompanied by an increased expression of the 5-HT1A receptor. CONCLUSIONS AND IMPLICATIONS: Our findings indicate that transfer of the main locus of hereditary catalepsy containing the 5-HT1A receptor from CBA mice to the C57BL/6 genetic background led to increased postsynaptic and decreased presynaptic functional responses of the 5-HT1A receptor. This characteristic establishes the B6-M76C line as an attractive model for the pharmacological screening of 5-HT1A receptor-related drugs specifically acting on either pre- or postsynaptic receptors. LINKED ARTICLES: This article is part of a themed section on Updating Neuropathology and Neuropharmacology of Monoaminergic Systems. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.13/issuetoc.
BACKGROUND AND PURPOSE: One important syndrome of psychiatric disorders in humans is catalepsy. Here, we created mice with different predispositions to catalepsy and analysed their pharmacological and behavioural properties. EXPERIMENTAL APPROACH: Two mouse lines, B6-M76C and B6-M76B, were created by transfer of the main locus of catalepsy containing the 5-HT1A receptor gene to the C57BL/6 genetic background. Behaviour, brain morphology, expression of key components of the serotoninergic system, and pharmacological responses to acute and chronic stimulation of the 5-HT1A receptor were compared. KEY RESULTS: B6-M76B mice were not cataleptic, whereas 14% of B6-M76C mice demonstrated catalepsy and decreased depressive-like behaviour. Acute administration of the 5-HT1A receptor agonist 8-OH-DPAT resulted in dose-dependent hypothermia and in decreased locomotion in both lines. Chronic 8-OH-DPAT administration abolished the 5-HT1A receptor-mediated hypothermic response in B6-M76C mice and increased locomotor activity in B6-M76B mice. In addition, 5-HT metabolism was significantly reduced in the hippocampus of B6-M76C mice, and this effect was accompanied by an increased expression of the 5-HT1A receptor. CONCLUSIONS AND IMPLICATIONS: Our findings indicate that transfer of the main locus of hereditary catalepsy containing the 5-HT1A receptor from CBA mice to the C57BL/6 genetic background led to increased postsynaptic and decreased presynaptic functional responses of the 5-HT1A receptor. This characteristic establishes the B6-M76C line as an attractive model for the pharmacological screening of 5-HT1A receptor-related drugs specifically acting on either pre- or postsynaptic receptors. LINKED ARTICLES: This article is part of a themed section on Updating Neuropathology and Neuropharmacology of Monoaminergic Systems. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.13/issuetoc.
Authors: Alexander V Kulikov; Daria V Fursenko; Nikita V Khotskin; Daria V Bazovkina; Victor A Kulikov; Vladimir S Naumenko; Ekaterina Yu Bazhenova; Nina K Popova Journal: Pharmacol Biochem Behav Date: 2014-04-26 Impact factor: 3.533
Authors: Alexander V Kulikov; Vladimir S Naumenko; Irina P Voronova; Maria A Tikhonova; Nina K Popova Journal: J Neurosci Methods Date: 2005-01-30 Impact factor: 2.390
Authors: M P Moisan; H Courvoisier; M T Bihoreau; D Gauguier; E D Hendley; M Lathrop; M R James; P Mormède Journal: Nat Genet Date: 1996-12 Impact factor: 38.330
Authors: Vladimir S Naumenko; Elena M Kondaurova; Daria V Bazovkina; Anton S Tsybko; Tatyana V Il'chibaeva; Nina K Popova Journal: J Neurosci Res Date: 2014-04-03 Impact factor: 4.164
Authors: E A Kulikova; D V Bazovkina; A E Akulov; A S Tsybko; D V Fursenko; A V Kulikov; V S Naumenko; E Ponimaskin; E M Kondaurova Journal: Br J Pharmacol Date: 2016-04-21 Impact factor: 8.739
Authors: Elena M Kondaurova; Alexander Ya Rodnyy; Tatiana V Ilchibaeva; Anton S Tsybko; Dmitry V Eremin; Yegor V Antonov; Nina K Popova; Vladimir S Naumenko Journal: Int J Mol Sci Date: 2020-11-20 Impact factor: 5.923